Nanonews
Research results, conferences, grants and company news from Nano1Health.
-
From qPCR to digital PCR: detecting drug-resistance biomarkers in dogs with low parasite loadsRead more
Our study in Parasites & Vectors shows that a 4-plex digital PCR assay detects Leishmania infantum drug-resistance biomarkers in clinical samples with low parasite loads, where qPCR reaches its limit.
-
From genomes to clinical samples: direct qPCR detects drug-resistance biomarkers in dogs with leishmaniosisRead more
Our validation study of LeishGenR™, the direct qPCR test for antileishmanial drug-resistance biomarkers, has been published in BMC Veterinary Research.
-
LeishGenR™ is now available to veterinarians across EuropeRead more
Our drug-resistance test for Leishmania infantum is now offered through two licensed reference laboratories: UranoVet in Spain and Portugal, and MyLav in Italy and the rest of Europe.
-
Nanopore genomes reveal drug-resistance and virulence profiles in Mediterranean Leishmania infantumRead more
Our whole-genome study of Leishmania infantum isolates from dogs and humans, published in Parasites & Vectors, found at least one drug-resistance biomarker in 80% of isolates.
-
Outstanding Poster Award at ECVIM-CA 2025 for our work on drug resistance in canine leishmaniosisRead more
Marina Carrasco-Martín and Clàudia Viñeta received the Outstanding Poster Award at the ECVIM-CA 2025 Congress in Maastricht for their poster on clinical applications of genomic drug-resistance detection.
-
Longitudinal metagenomic study shows no significant gut microbiome disruption in dogs treated for leishmaniosisRead more
The first longitudinal metagenomic study of the gut microbiota in dogs receiving standard antileishmanial treatment, published in Animal Microbiome.
-
LeishGenApp and LeishGenR™: genomic platforms for drug-resistance biomarkers in Leishmania infantumRead more
Two platforms that detect drug-resistance biomarkers in Leishmania infantum, one from cultured isolates and one directly from clinical samples.
-
N1H-Cloud and LeishGen showcased at London Calling 2024Read more
Our team presented its Leishmania resistance platforms and N1H-Cloud at Oxford Nanopore's user meeting, where Marina Carrasco's poster was Highly Commended.
-
LeishGen wins Best Oral Communication at ALIVE2 in NiceRead more
Marina Carrasco's talk on drug-resistance biomarkers in Leishmania infantum won the research award at the LeishVet congress.
-
Industrial Doctorate and Torres Quevedo grants at Nano1HealthRead more
Three competitive grants in 2023 support our work on identifying pathogens and antimicrobial resistance.
-
Spanish National Day for the Prevention of LeishmaniosisRead more
A campaign with Miscota and Elanco supports our research on drug-resistance biomarkers in Leishmania infantum.
-
Preliminary results on drug-resistance biomarkers in Leishmania infantum at London Calling 2022Read more
First results from nanopore sequencing of Leishmania genomes, presented at the Oxford Nanopore conference in London.
-
Whole-genome sequencing of Leishmania infantum isolates to identify biomarkers of pathogenicity and drug resistanceRead more
We are sequencing Leishmania genomes from several Mediterranean countries to find structural variants that predict virulence and treatment response.
-
Joan Martí-Carreras joins Nano1Health as postdoctoral researcherRead more
A virologist and bioinformatician with deep experience in nanopore sequencing joins the team through the Neotec project.
-
Nano1Health moves to the UAB Research ParkRead more
Since February 2022 we work from the Eureka building, the business incubator of the UAB Research Park in Bellaterra.
-
Nano1Health develops a genomic analysis platform for Leishmania infantum in a Neotec projectRead more
A CDTI Neotec grant funds an agile platform for detecting pathogenicity and drug-resistance markers in the parasite's genome.